ClinicalTrials.gg
RecruitingNCT05845424DECISION-CALUpdated Jan 14, 2025

High-intensity Statin and Ezetimibe Therapy for Asymptomatic Patients With Positive Coronary Calcium

A Phase 4 interventional study of Guideline directed statin therapy and High intensity statin plus ezetimibe therapy in Coronary Artery Calcification, Metabolic Syndrome and Dyslipidemias, sponsored by Samsung Medical Center. Recruiting at 1 site in Korea, Republic of. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2025-01-14.

Sponsored by Samsung Medical Center · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2023; still recruiting 3 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
6,000
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 53 studies in Metabolic Syndrome with a site in Korea, Republic of — 4 open to participants now, 4 under way, none of them phase 3. Metabolic Syndrome · Korea, Republic of.

Planned enrollment
Largest of 31
6,000 · median 67
Started
2023
the only one that year
Phase 4
11 of 53
1 open now
Registered
50th of 53
by date

Among the 53 studies in Metabolic Syndrome with a site in Korea, Republic of, this one has the largest planned enrollment of the 31 interventional ones that give a count, is the only one that started in 2023, is one of 11 in phase 4, and was the 50th registered.

Metabolic Syndrome

2,119 studies on the registry are indexed under Metabolic Syndrome; 350 are open to participants now.

Browse Metabolic Syndrome studies →

Open to participants now

4 of the 53 studies in Metabolic Syndrome with a site in Korea, Republic of are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 234 Metabolic Syndrome studies recruiting now, 70 (30%) set no upper age limit and 135 (58%) stop at 75 or younger; 20 take children under 18; 81 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Metabolic Syndrome with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The aim of this study is to compare safety and efficacy between the aggressive treatment with combination of high-intensity statin and ezetimibe and the current standard lipid lowering treatment in asymptomatic patients with presence of coronary calcification.

Read the detailed description

Atherosclerotic cardiovascular diseases (ASCVD), such as myocardial infarction (MI), ischemic stroke, or peripheral arterial disease, are the leading cause of morbidity and mortality worldwide. The causality of low-density lipoproteins cholesterol (LDL-C) level in the development of ASCVD is well demonstrated in previous studies. After introducing LDL-C lowering agents, multiple large-scale randomized clinical trials have demonstrated lower cardiovascular events with lowering LDL-C levels. In particular, for secondary prevention, more aggressive control of LDL-C levels with high-intensity statin therapy significantly reduced cardiovascular events compared with moderate-intensity statin therapy. In addition, the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) proved the clinical efficacy of additive ezetimibe for incrementally lowering of LDL-C levels in patients with acute coronary syndrome. However, there has been limited evidence regarding the efficacy and safety of aggressive lipid-lowering strategy using high-intensity statin with a combination of ezetimibe for primary prevention of cardiovascular events among persons without cardiovascular disease. Although the Heart Outcomes Prevention Evaluation (HOPE)-3 and Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trials consistently identified that the use of rosuvastatin (10 mg or 20 mg) was significantly associated with reduced future risk of major cardiovascular events in patients who did not have cardiovascular disease, those studies have been focused on the use of statin, not on the intensity of statin.

The coronary artery calcium (CAC) scan, a marker of subclinical coronary atherosclerosis, has become popular for individuals at risk for atherosclerotic cardiovascular disease. CAC is strongly associated with atherosclerotic burden and predicts coronary heart disease events and mortality, regardless of their age, sex, race, or ASCVD risk. Furthermore, the progression of CAC is associated with an increased risk for future hard and total coronary heart disease events. The use of CAC scoring was associated with significant improvements in the reclassification and discrimination of incident ASCVD. Nevertheless, the current guidelines recommend CAC measurement for selected cases only with borderline or intermediate risk of ASCVD to guide the use of statin or not. However, in real-world practice, CAC testing is increasingly being promoted to the public as a means of self-assessment of cardiovascular risk and is widely being used regardless of ASCVD risk. Considering that statin has additional properties, including atherosclerotic plaque stabilization, oxidative stress reduction, enhancement of endothelial function, and a decrease in vascular inflammation beyond their lipid-lowering effect, aggressive treatment with a high-intensity statin plus ezetimibe combination might have beneficial effects on the long-term clinical outcomes for asymptomatic patients with significant coronary calcium (Agatston Score ≥ 100) compared with standard lipid-lowering therapy endorsed by the current guidelines.

Therefore, the purpose of DECISION-CALCIUM (Comparison of Efficacy and Safety of High-Intensity Statin and Ezetimibe Combination versus StanDard carE in AsymptomatiC PatIentS wIth Presence of COroNary Artery CALCIUM) trial is to compare the efficacy and safety of the aggressive lipid-lowering therapy with combination of high-intensity statin and ezetimibe, compared with the current standard lipid-lowering therapy in asymptomatic patients with significant coronary calcification for primary prevention.

03

Conditions studied

  • Coronary Artery Calcification
  • Metabolic Syndrome
  • Dyslipidemias
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject must be at least 40 years of age.
  • Asymptomatic patients with presence of coronary calcification (Agatston Score ≥ 100)
  • low-density lipoproteins cholesterol (LDL-C) \<190 mg/dL

Exclusion criteria

Exclusion Criteria:

  • Objective evidence of at least moderate inducible ischemia requiring revascularization treatment
  • History of cerebrovascular disease
  • History of coronary or peripheral arterial revascularization
  • Active liver disease or persistent unexplained serum transaminase elevations more than 2 times the
  • History of any adverse drug reaction requiring discontinuation of statin (e, g. rhabdomyolysis)
  • Allergy or sensitivity to any statin or ezetimibe
  • Concurrent treatment with cyclosporine or a condition likely to result in organ transplantation and the need for cyclosporine
  • Pregnancy or breast feeding
  • Non-cardiac co-morbid conditions are present with \<1 year or that may result in protocol non-compliance (per site investigator's medical judgment)
  • Unwillingness or inability to comply with the procedures described in this protocol.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
6,000 participants (estimated)

Study arms

  • Experimental
    Aggressive treatment arm

    In this group, high-intensity statin (rosuvastatin 20mg) combined with ezetimibe 10 mg will be prescribed regardless of patients' age, concomitant diabetes mellitus, or ASCVD risk.

    Drug: High intensity statin plus ezetimibe therapy

  • Active comparator
    Standard treatment arm

    In this group, lipid lowering therapy will be followed according to the current guideline recommendation. A moderate-intensity statin (rosuvastatin 5 mg) will be prescribed for patients over 75 years of age or with diabetes mellitus. For non-diabetic patients aged 40-75 years, the use of statins will be determined by calculating the ASCVD risk score. (ASCVD risk \<7.5%: no statin use, ≥7.5 - \<20%: moderate-intensity statin \[rosuvastatin 5mg\], ≥ 20%: high-intensity statin \[rosuvastatin 20mg\])

    Drug: Guideline directed statin therapy

Interventions

  • DrugGuideline directed statin therapy

    At least moderate intensity statin, recommended by the current guideline based on the ASCVD risk

  • DrugHigh intensity statin plus ezetimibe therapy

    Rosuvastatin 20 mg + Ezetimibe 10 mg

06

What researchers measure

Primary outcomes

  1. Major adverse cardiovascular events

    a composite of death from any causes, myocardial infarction, stroke, unplanned coronary revascularization, or other arterial revascularization procedure

    Time frame: up to 4.5 years of median follow-up (till 3 year after the last patient enrollment)

Secondary outcomes

  1. All-cause death

    Death from any causes

    Time frame: up to 4.5 years of median follow-up (till 3 year after the last patient enrollment)

  2. Cardiovascular death

    Death from cardiovascular causes

    Time frame: up to 4.5 years of median follow-up (till 3 year after the last patient enrollment)

  3. Stroke

    Ischemic or hemorrhagic stroke

    Time frame: up to 4.5 years of median follow-up (till 3 year after the last patient enrollment)

  4. Unplanned coronary revascularization

    revascularization procedure to coronary artery

    Time frame: up to 4.5 years of median follow-up (till 3 year after the last patient enrollment)

  5. Arterial revascularization procedure

    All arterial revascularization procedure

    Time frame: up to 4.5 years of median follow-up (till 3 year after the last patient enrollment)

  6. Major bleeding

    Bleeding Academic Research Consortium (BARC) type 3-5

    Time frame: up to 4.5 years of median follow-up (till 3 year after the last patient enrollment)

  7. Bleeding

    BARC type 2-5

    Time frame: up to 4.5 years of median follow-up (till 3 year after the last patient enrollment)

  8. Heart failure hospitalization

    Hospitalization due to heart failure

    Time frame: up to 4.5 years of median follow-up (till 3 year after the last patient enrollment)

  9. Coronary calcium progression

    Delta CAC

    Time frame: up to 4.5 years of median follow-up (till 3 year after the last patient enrollment)

  10. Changes of LDL-C

    Delta LDL-C

    Time frame: up to 4.5 years of median follow-up (till 3 year after the last patient enrollment)

  11. New-onset diabetes mellitus

    Occurence of new-onset diabetes mellitus

    Time frame: up to 4.5 years of median follow-up (till 3 year after the last patient enrollment)

  12. Hepatic disorder requiring discontinuation of statin

    Occurence of hepatic disorder requiring discontinuation of statin

    Time frame: up to 4.5 years of median follow-up (till 3 year after the last patient enrollment)

  13. muscle-related adverse events

    Occurence of muscle-related adverse events due to statin

    Time frame: up to 4.5 years of median follow-up (till 3 year after the last patient enrollment)

  14. Proportion of patients with LDL-C < 100mg/dL

    Proportion of patients with LDL-C \< 100mg/dL

    Time frame: up to 4.5 years of median follow-up (till 3 year after the last patient enrollment)

  15. Proportion of patients with LDL-C < 70mg/dL

    Proportion of patients with LDL-C \< 70mg/dL

    Time frame: up to 4.5 years of median follow-up (till 3 year after the last patient enrollment)

07

Study locations

1 of 1 sites recruiting
  • SamsungMedicalCenter
    Seoul, 06351, Korea, Republic of
    Recruiting
    • Seunghyuk Choi, PhMD · Contact82-2-3410-3437
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2023 (actual). Primary completion is estimated for Jun 2029, 71 months after the start.

Of 32 phase 4 interventional studies under Metabolic Syndrome, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 57. This study's planned 71 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 25, 2023
First posted
May 6, 2023
StartActual
Jul 3, 2023
Primary completionEst.
Jun 30, 2029
CompletionEst.
Jun 30, 2030
Last update
Jan 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05845424
Responsible party
Seung-Hyuk Choi (Professor, Samsung Medical Center) — Principal investigator
First posted
May 6, 2023
Start date
Jul 3, 2023
Primary completion
Jun 30, 2029 (estimated)
Completion
Jun 30, 2030 (estimated)
Last update
Jan 14, 2025

Study contacts

Seung-Hyuk Choi, MD
Contact
sh1214.choi@samsung.com
82-2-3410-3419
Ki Hong Choi, MD
Contact
cardiokh@gmail.com
82-2-3410-6653
Seung-Hyuk Choi
principal investigator · Samsung Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion